The epidemiology of generalized anxiety disorder in Europe

Roselind Lieb, Eni Becker, Carlo Altamura

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

The objective of this paper is to provide a review on available data to date on the epidemiology of GAD in Europe, and to highlight areas for future research. MEDLINE searches were performed and supplemented by consultations with experts across Europe to identify non-published reports. Despite variations in the design of studies, available data suggest that (a) about 2% of the adult population in the community is affected (12-month prevalence), (b) GAD is one of the most frequent (up to 10%) of all mental disorders seen in primary care, (c) GAD is a highly impairing condition often comorbid with other mental disorders, (d) GAD patients are high utilizers of healthcare resources, and (e) despite the high prevalence of GAD in primary care, its recognition in general practice is relatively low. Marked data deficits are: lack of data from eastern European countries, lack of information about the natural course of GAD in unselected samples, the vulnerability and risk factors involved in the aetiology of GAD and lack of data about adequate and inappropriate treatments in GAD patients as well as the associated and societal costs of GAD.

Original languageEnglish
Pages (from-to)445-452
Number of pages8
JournalEuropean Neuropsychopharmacology
Volume15
Issue number4
DOIs
Publication statusPublished - Aug 2005

Fingerprint

Anxiety Disorders
Mental Disorders
Primary Health Care
Epidemiology
MEDLINE
General Practice
Referral and Consultation
Delivery of Health Care
Costs and Cost Analysis
Population
Therapeutics

Keywords

  • Epidemiology
  • Europe
  • Generalized anxiety disorder
  • Incidence
  • Prevalence

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Neurology
  • Pharmacology
  • Psychology(all)

Cite this

The epidemiology of generalized anxiety disorder in Europe. / Lieb, Roselind; Becker, Eni; Altamura, Carlo.

In: European Neuropsychopharmacology, Vol. 15, No. 4, 08.2005, p. 445-452.

Research output: Contribution to journalArticle

Lieb, Roselind ; Becker, Eni ; Altamura, Carlo. / The epidemiology of generalized anxiety disorder in Europe. In: European Neuropsychopharmacology. 2005 ; Vol. 15, No. 4. pp. 445-452.
@article{0301b2233c664f3ba397c1a3c87a76ff,
title = "The epidemiology of generalized anxiety disorder in Europe",
abstract = "The objective of this paper is to provide a review on available data to date on the epidemiology of GAD in Europe, and to highlight areas for future research. MEDLINE searches were performed and supplemented by consultations with experts across Europe to identify non-published reports. Despite variations in the design of studies, available data suggest that (a) about 2{\%} of the adult population in the community is affected (12-month prevalence), (b) GAD is one of the most frequent (up to 10{\%}) of all mental disorders seen in primary care, (c) GAD is a highly impairing condition often comorbid with other mental disorders, (d) GAD patients are high utilizers of healthcare resources, and (e) despite the high prevalence of GAD in primary care, its recognition in general practice is relatively low. Marked data deficits are: lack of data from eastern European countries, lack of information about the natural course of GAD in unselected samples, the vulnerability and risk factors involved in the aetiology of GAD and lack of data about adequate and inappropriate treatments in GAD patients as well as the associated and societal costs of GAD.",
keywords = "Epidemiology, Europe, Generalized anxiety disorder, Incidence, Prevalence",
author = "Roselind Lieb and Eni Becker and Carlo Altamura",
year = "2005",
month = "8",
doi = "10.1016/j.euroneuro.2005.04.010",
language = "English",
volume = "15",
pages = "445--452",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier Science B.V.",
number = "4",

}

TY - JOUR

T1 - The epidemiology of generalized anxiety disorder in Europe

AU - Lieb, Roselind

AU - Becker, Eni

AU - Altamura, Carlo

PY - 2005/8

Y1 - 2005/8

N2 - The objective of this paper is to provide a review on available data to date on the epidemiology of GAD in Europe, and to highlight areas for future research. MEDLINE searches were performed and supplemented by consultations with experts across Europe to identify non-published reports. Despite variations in the design of studies, available data suggest that (a) about 2% of the adult population in the community is affected (12-month prevalence), (b) GAD is one of the most frequent (up to 10%) of all mental disorders seen in primary care, (c) GAD is a highly impairing condition often comorbid with other mental disorders, (d) GAD patients are high utilizers of healthcare resources, and (e) despite the high prevalence of GAD in primary care, its recognition in general practice is relatively low. Marked data deficits are: lack of data from eastern European countries, lack of information about the natural course of GAD in unselected samples, the vulnerability and risk factors involved in the aetiology of GAD and lack of data about adequate and inappropriate treatments in GAD patients as well as the associated and societal costs of GAD.

AB - The objective of this paper is to provide a review on available data to date on the epidemiology of GAD in Europe, and to highlight areas for future research. MEDLINE searches were performed and supplemented by consultations with experts across Europe to identify non-published reports. Despite variations in the design of studies, available data suggest that (a) about 2% of the adult population in the community is affected (12-month prevalence), (b) GAD is one of the most frequent (up to 10%) of all mental disorders seen in primary care, (c) GAD is a highly impairing condition often comorbid with other mental disorders, (d) GAD patients are high utilizers of healthcare resources, and (e) despite the high prevalence of GAD in primary care, its recognition in general practice is relatively low. Marked data deficits are: lack of data from eastern European countries, lack of information about the natural course of GAD in unselected samples, the vulnerability and risk factors involved in the aetiology of GAD and lack of data about adequate and inappropriate treatments in GAD patients as well as the associated and societal costs of GAD.

KW - Epidemiology

KW - Europe

KW - Generalized anxiety disorder

KW - Incidence

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=19844367388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19844367388&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2005.04.010

DO - 10.1016/j.euroneuro.2005.04.010

M3 - Article

VL - 15

SP - 445

EP - 452

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 4

ER -